ESR1 and breast carcinoma: In the ECTOII trial [15], pCR was more common in patients with estrogen receptor-negative (ER−) breast cancer than in patients with estrogen receptor-positive (ER+) breast cancer and capecitabine was only associated with a higher frequency of pCR only in ER+ cancer patients who received only AT-CMX neoadjuvant therapy.